Table 5.

Vorinostat in CTCL: Response rates^a

	400 mg qd (n = 13)	300 mg bid × 3–5 d/wk (n = 11)	300 mg bid 400 mg qd (n = 9)
Partial response	4 (31%)	1 (9%)	3 (33%)
marked (patients)	2	1	3
Median PR duration (range/weeks)	15 (8–24)	16 (8–24)	13 (3–21)
Mean time to PR (weeks)	11	4	11
LN regression at 4 wks (patients)	7 of 9	3 of 8	5 of 9
>50%↓ pruritus (patients)	9 of 11	8 of 12	4 of 8

^aPhase 2A

Abbreviations: LN, lymph node; PR, partial response.